Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea flag South Korea · Delayed Price · Currency is KRW
33,250
+950 (2.94%)
At close: Aug 24, 2026

Next Biomedical Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
13,9926,7894,9503,9023,01422,016
Short-Term Investments
3,0009,30520,76610,38811,783-
Trading Asset Securities
17,99920,90415,892---
Cash & Short-Term Investments
34,99136,99841,60914,29014,79722,016
Cash Growth
11.63%-11.08%191.17%-3.43%-32.79%226.66%
Accounts Receivable
4,0852,2361,845918.64314.3118.67
Other Receivables
222.5792.97321.39214.28170.8486.52
Receivables
4,3082,3292,1671,133485.15205.19
Inventory
3,0593,0362,5812,1691,9401,313
Prepaid Expenses
180.03247.28190.08155.85207.32138.44
Other Current Assets
1,699657.75341.35220.790.865.69
Total Current Assets
44,23643,26746,88817,96817,52123,739
Property, Plant & Equipment
13,88214,01811,27011,42811,73511,918
Long-Term Investments
4,097907.78--2,6373,737
Other Intangible Assets
334.23310.64344.38217.63222.19288.71
Long-Term Accounts Receivable
0-0-0-0-0-0
Other Long-Term Assets
1,029761.06342.7529.4821.3537.51
Total Assets
63,57959,26558,84429,64332,13639,720

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
71.947.6913.3758.1645.024.1
Accrued Expenses
588.65179.5126.23121.14106.9396.48
Short-Term Debt
2,1602,1605,6005,6005,6005,600
Current Portion of Long-Term Debt
4,0654,4934,5394,8974,8005,200
Current Portion of Leases
34.6539.8426.3741.5135.632.24
Other Current Liabilities
1,8991,1241,579714.37452.972,115
Total Current Liabilities
8,8198,04411,88411,43311,04113,048
Long-Term Debt
639950.66763.5933.5450020,873
Long-Term Leases
53.968.4920.5846.981.6346.55
Pension & Post-Retirement Benefits
1,708944.49749.44559.45471.1385.02
Other Long-Term Liabilities
3,1971,151235.35218.84368.8284.7
Total Liabilities
14,41611,15813,65313,19112,46234,636

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
4,1394,1024,0433,1743,1103,105
Additional Paid-In Capital
114,506111,130107,23461,63260,67960,603
Retained Earnings
-71,375-70,597-70,181-72,984-65,367-59,673
Comprehensive Income & Other
1,8923,4724,0952,2771,3241,049
Total Common Equity
49,16348,10745,191-5,901-253.845,084
Shareholders' Equity
49,16348,10745,19116,45219,6745,084
Total Liabilities & Equity
63,57959,26558,84429,64332,13639,720

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
6,9537,71210,94911,51911,01731,751
Net Cash (Debt)
28,03829,28630,6592,7713,780-9,735
Net Cash Growth
41.61%-4.48%1006.61%-26.70%--
Net Cash Per Share
3431.483603.034256.48441.28608.67-2011.96
Filing Date Shares Outstanding
8.228.28.096.286.214.84
Total Common Shares Outstanding
8.228.28.096.286.214.84
Working Capital
35,41835,22435,0046,5366,48010,691
Book Value Per Share
5979.665863.935588.37-939.89-40.881050.64
Tangible Book Value
48,82947,79644,847-6,119-476.034,795
Tangible Book Value Per Share
5939.015826.065545.78-974.55-76.65990.97
Land
5,6185,6185,2775,2775,2775,277
Buildings
7,3187,3165,7865,7865,7865,786
Machinery
2,5782,5661,5981,4301,3971,504
Construction In Progress
158.89215.3799.29119.06150.11188.87